According to Futu News on the 25th, Novax Pharmaceuticals announced the launch of the third phase of COVID-19 vaccine research in the UK and trials in the United States in mid-October. At one point, the company's US stock rose more than 7% in after-hours trading.As of press time, Novax rose 6.9% to $109.51 in after-hours trading.

Novakis teamed up with the British government's Vaccine working Group (Vaccines Taskforce) on Thursday to begin phase III trials of its experimental Covid-19 vaccine.The trial is expected to recruit and test up to 10,000 participants between the ages of 18 and 84 in the next four to six weeks.

The company said the test data would support regulators in the UK, EU and other countries to submit applications for permits.The trial will recruit at least 25 per cent of participants over the age of 65, giving priority to those most affected by COVID-19.

The study had two main objectives. The first was for COVID-19 patients who first developed symptomatic symptoms confirmed by PCR and were free of infection for at least 7 days after the second vaccination. The second was to vaccinate volunteers who had not been infected with COVID-19 virus and developed moderate or severe symptomatic COVID-19 confirmed by PCR within at least 7 days.

Novak announced on its website on July 7 that he had been selected to participate in Operation curvature Express (Operation Warp Speed,OWS) and received a $1.6 billion award from the US government, which, under the agreement, will be used for late-stage clinical studies of Novak's candidate COVID-19 vaccine NVX CoV2373, including a key phase III clinical trial.